First year of Lyme disease surveillance data collected using revised 2022 case definition

This surveillance report describes the first year of Lyme disease data collection in the United States following implementation of a revised case definition in 2022. The population was the United States population, and the comparator was cases reported during 2017-2019. No specific results, effect sizes, absolute numbers, p-values, confidence intervals, or direction of change were reported for the primary outcome of Lyme disease surveillance data.

No safety, adverse events, serious adverse events, discontinuations, or tolerability data were reported. Secondary outcomes were not specified. The follow-up period was the first year of data collection using the new definition.

Key limitations were not reported. Funding sources and conflicts of interest were not reported. The practice relevance was not reported. This is a descriptive surveillance report with no comparative results presented, so no causal inferences or changes in disease burden can be assessed from the provided information.

The report represents initial administrative data collection under a new definitional framework. Clinicians should await detailed epidemiological analyses comparing pre- and post-implementation periods before drawing any conclusions about trends in Lyme disease incidence or distribution.